The Applanation Tonometry in GCA Pilot
Key facts
- Who runs it
- Centre Integre Universitaire de Sante et Services Sociaux du Nord de l'ile de Montreal
- Where
- Canada1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Active, not recruiting
- People taking part
- 146 people, planned
- Started
- 30 Jul 2025
- Expected to end
- Jul 2027
- Type of study
- Observational, 2 groups
- Treatments tested
- Applanation tonometry
- Standardized GCA assessment
- Repeat applanation tonometry (optional)
- Record updated
- 21 October 2026
Who can take part
- Age
- 50 years to 99 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 10 criteriaShow less
Who can take part
- To be included in ATOM-GCA, participants must meet all the following criteria:
- Age > 50 years
- Referral for suspected, new-onset GCA
- Ability to understand and willingness to sign an informed consent form
- Willingness to comply with study visits and procedures
Who cannot take part
- Current use of systemic glucocorticoids, with the following duration at the baseline visit:; ≥ 14 consecutive days of oral glucocorticoids in the previous 30 days, or; ≥ 7 consecutive days of oral glucocorticoids if intravenous glucocorticoids were administered in the previous 30 days
- Current use of any conventional or biologic immunosuppressive therapy
- Temporal artery biopsy prior to the study visit
- An individual who meets any of these criteria will be excluded from ATOM-GCA:
- Referral for a suspected GCA relapse
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The Applanation Tonometry in Giant Cell Arteritis (ATOM-GCA) study will answer the following questions:
Read full original descriptionShow less
1. How does PWV, measured by applanation tonometry of temporal arteries, differ between patients with and without a final diagnosis of GCA (based on pre-defined criteria 6 months after inclusion)? 2. What is the diagnostic accuracy and positivity cutoff of the PWV, measured by applanation tonometry, in detecting:
1. A clinical diagnosis of GCA (based on pre-defined criteria 6 months after inclusion)? 2. Inflammation of temporal arteries on high-resolution ultrasound? 3. What is the acceptability and adherence of repeat applanation tonometry during the follow-up period in patients with GCA?
The 2 groups in the trial
- GCA group
Definite confirmation of GCA will occur 6 months after study inclusion, following the phone follow-up, and will require all the following features: 1) initial symptoms and clinical evolution consistent with GCA; 2) at least one positive test for cranial GCA (ultrasound of temporal arteries, temporal artery biopsy, cranial MRI, cranial PET); and 3) satisfies the 2022 ACR-EULAR classification criteria for GCA.
Treatment: Applanation tonometry, Standardized GCA assessment, and Repeat applanation tonometry (optional)
- Non-GCA group
Participants who do not meet the criteria (above) for GCA at month 6.
Treatment: Applanation tonometry and Standardized GCA assessment
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- The Applanation Tonometry in Giant Cell Arteritis Pilot
- Record updated
- 21 October 2026